Europe Breast Implants Market size surpassed USD 470 million in 2021 and is predicted to exhibit a CAGR of 9% between 2022 and 2028.
The market growth can be credited to the growing prevalence of breast cancer. According to EURACTIV France, breast cancer has emerged as the most common type of cancer in Europe, with over 400,000 cases per year. This growing disease burden will influence patients to undertake procedures like mastectomy to remove cancer cells in breast tissues and in turn, augment the demand for implants to restore breast shape and volume.
Get more details on this report - Request Free Sample PDF
In the European Union, organized screening programs are recommended for various disease types including breast cancer to deliver quality services. Such initiatives, alongside the mounting acceptance of cosmetic surgeries, are amplifying the consumption of breast implants in the region.
Furthermore, with the rapid technological advancement, the development of advanced breast implants in terms of design, material, and fill volumes has accelerated, reducing adverse outcomes like implant wrinkling, and rippling in patients. This increasing product innovation and the presence of skilled plastic surgeons are generating growth opportunities for the industry.
Impact of COVID-19 on the Europe Breast Implants Market Growth
The novel coronavirus pandemic has had a substantial and long-lasting impact on care provision, mainly in the field of cancer care. The pandemic has also led to a decline in access to life-saving screening programs and diagnostics in the European Union, creating a major hindrance to the expansion of breast implantation service providers.
However, with the gradual ease of the COVID-19 restrictions, several re-engagement strategies have been incorporated to reduce delays in cancer diagnosis and treatment. These factors will assert a positive influence on the demand for breast implants among cancer patients who opt for breast reconstruction surgeries after mastectomy.
The round breast implants market will see robust demand in Europe through 2028, credited to their ability to rotate and shift freely without distorting the shape and structure of the breasts. This favorable feature can give the breasts a more natural appearance, thereby adding impetus to the industry expansion across Europe.
The usage of implants for breast reconstruction applications segment will increase steadily till 2028, due to the proliferating number of patients diagnosed with breast cancer and the potential rise in demand for breast implantation surgeries to restore its volume after mammoplasty.
The breast implants with textured shells will gain massive popularity during the forecast period, attributed to their advantages like low rates of capsular contracture, decreased malposition, and reduced rates of reoperation, making them a great fit for breast augmentation procedures.
The silicone breast implants market revenue in Germany will cross USD 140 million by 2028, impelled by the presence of leading companies, including Polytech Health & Aesthetics, which design silicone implants for varied reconstructive and aesthetic plastic surgeries. Germany will emerge as a major hub for breast implant manufacturers, given the increasing number of plastic surgeons and the growing acceptance of breast reconstruction and augmentation procedures.
Since hospitals provide a range of curative diagnostic, and rehabilitation services, the popularity of breast implantation surgery in hospitals will grow. They also maintain well-established infrastructures and organized nursing, medical, and other healthcare professionals.
Some of the leading companies involved in the Europe breast implants market include GC Aesthetics, Polytech Health & Aesthetics, Sebbin SAS, Cereplas, Laboratory Arion, Allergan Plc, Establishment Labs SA, Ideal Implant Inc., Mentor Worldwide LLC, and Sientra.
Innovative product launches and collaborations are among the key initiatives undertaken by these firms to gain a competitive advantage over rivals. For instance, in May 2022, GC Aesthetics, Inc. unveiled FixNip NRI, its Nipple Areola Complex Reconstruction Implants, to address the clinical need of women. These implants were intended to be initially launched in main European Territories.